Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
ALTMAN STEVEN R reported acquisition or exercise transactions in this Form 4 filing.
DexCom director Steven R. Altman received a grant of 5,565 restricted stock units of DexCom common stock. The award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or DexCom's 2027 Annual Meeting of Stockholders. Each unit represents a contingent right to receive one share of common stock upon settlement. Following the grant, Altman holds 5,565 shares directly from this award and 63,667 shares indirectly through the Altman Family Trust, where he serves as trustee.
Malady Kyle reported acquisition or exercise transactions in this Form 4 filing.
DexCom Inc. director Kyle Malady received an equity award in the form of restricted stock units. The Form 4 reports a grant of 5,575 shares of Common Stock at no cash cost as a compensation-related award, bringing his direct holdings to 28,242 shares.
The award is structured as RSUs, each representing a contingent right to receive one DexCom share upon settlement. According to the terms, 100% of the RSU award will vest on the earlier of one year after the May 28, 2026 grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders.
AUGUSTINOS NICHOLAS reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Nicholas Augustinos reported a new equity award and updated holdings. He received a grant of 5,575 restricted stock units (RSUs) on May 28, 2026, with each RSU representing one share of Dexcom common stock upon settlement.
The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Following this award, he holds 5,575 shares directly and 38,457 shares indirectly through the Kirschner/Augustinos Revocable Trust, where he serves as a trustee.
FOLETTA MARK G reported acquisition or exercise transactions in this Form 4 filing.
Dexcom director Mark G. Foletta received a grant of 6,331 restricted stock units (RSUs) of Dexcom common stock. The award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Each RSU represents a contingent right to receive one share of common stock upon settlement. After the grant, Foletta holds 6,331 shares directly and 56,852 shares indirectly through The Foletta Family Trust DTD 1/30/2015, where he serves as trustee.
Heller Bridgette P reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Bridgette P. Heller received an equity award of 5,575 restricted stock units (RSUs) of common stock. The RSU grant was made on May 28, 2026 at no cash cost to her and is compensation-related, not an open-market purchase. The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. After this award, Heller directly holds 30,582 shares of Dexcom common stock.
Osterloh Albert Frederick IV reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Albert Frederick Osterloh IV received an equity grant of 1,630 restricted stock units (RSUs) of Dexcom common stock on May 28, 2026. The award was granted at no cash cost as part of compensation, not through an open-market purchase.
All 1,630 RSUs will vest on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. After this grant, Osterloh holds 8,691 unvested RSUs in total, including 7,061 RSUs granted on February 26, 2026 that are scheduled to vest through February 26, 2029.
Driscoll Rimma reported acquisition or exercise transactions in this Form 4 filing.
DexCom Inc. director Rimma Driscoll received a compensation-related stock award. She was granted 5,605 shares of DexCom common stock in the form of restricted stock units at a price of $0.00 per share.
The RSU award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders. Each restricted stock unit represents a contingent right to receive one DexCom common share upon settlement.
After this award, Driscoll directly holds 17,319 DexCom shares, which include 6,941 unvested restricted stock units. Of these unvested units, 5,605 were granted on May 28, 2026 and 1,336 were granted on August 24, 2023, scheduled to vest through August 24, 2026.
Ashley Euan A. reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Euan A. Ashley received an equity grant of 5,565 restricted stock units (RSUs) on May 28, 2026. The award carries no purchase price and is structured as stock-based compensation, not an open-market share purchase.
According to the terms, 100% of this RSU award will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. After this grant, Ashley holds 12,731 unvested RSUs in total, including 7,166 RSUs granted on October 24, 2025 that are scheduled to vest in tranches through October 24, 2028.
Collins Richard Alexander reported acquisition or exercise transactions in this Form 4 filing.
DexCom director Richard Alexander Collins reported a new equity award and his current holdings. He received a grant of 5,605 shares of DexCom common stock in the form of restricted stock units at a stated price of $0.00 per share. The RSU award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders. Each restricted stock unit represents a contingent right to receive one share of DexCom common stock upon settlement. Collins also reported indirect ownership of 40,162 DexCom common shares held by the Richard A. Collins Revocable Trust, for which he serves as trustee.